Viridian Therapeutics, Inc. (VRDN) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 2.08B USD. 52-week range 13.18 to 34.29 USD. Data as of 2026-10-09.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' ...